Parkinson’s Disease (Intermediate to Advanced) | Decision Base | US/EU | 2015

In a Market of Entrenched, Effective, and Mostly Generic Therapies, Where Do Physicians and Payers Identify Areas for Differentiation?

The prevalence of Parkinson’s disease (PD) will approach 3 million cases in the major pharmaceutical markets by 2023. A substantial portion of PD patients fall in the intermediate to advanced disease stage and are experiencing levodopa-induced motor response complications (MRCs), such as motor fluctuations and dyskinesias. MRCs are one of the primary ongoing clinical challenges in the management of PD and represent a viable opportunity for new therapeutic interventions. The PD pipeline is rich with emerging therapies, many of them targeting MRCs, including reformulations of current agents, new drugs from current PD drug classes, and therapies with new-to-PD mechanisms of action, such as adenosine A2A receptor antagonists. However, the extent to which therapies in development will fulfill the unmet need to better address MRCs remains to be seen.

launch Related Market Assessment Reports